For the Inventor, By the Inventor

Enter assignee name

Oxford, United Kingdom

Prosidion Limited

USPTO Granted Patents = 16

CIPO Patents = 2

EPO Patents = 11

Forward Citations = 101

Loading Chart...

Loading Chart...

39 inventors (with patents filed for the assignee):

Martin James Procter (7 out of 24 patents)

Matthew Colin Thor Fyfe (7 out of 15 patents)

Karen Lesley Schofield (6 out of 12 patents)

4. Chrystelle Marie Rasamison (5 out of 6 patents)

5. Stuart Edward Bradley (5 out of 15 patents)

6. Hans-Ulrich Demuth (4 out of 66 patents)

7. Lisa Sarah Gardner (4 out of 4 patents)

8. Gerard Hugh Thomas (4 out of 6 patents)

9. Vilasben Kanji Shah (4 out of 10 patents)

10. Thomas Martin Krulle (3 out of 8 patents)

11. Torsten Hoffmann (3 out of 29 patents)

12. Kosuke Yasuda (3 out of 15 patents)

13. Maseo Nawano (3 out of 3 patents)

14. Jason Bloxham (2 out of 5 patents)

15. Colin Peter Sambrook-Smith (2 out of 2 patents)

16 patents: Sort by Forward Citations

1. 8664397 - Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase (2014-03-04),

2. 8278442 - Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders (2012-10-02),

3. 8207147 - Heterocyclic derivatives as GPCR receptor agonists (2012-06-26),

4. 8193359 - G-protein coupled receptor agonists (2012-06-05),

5. 8173807 - Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists (2012-05-08),

6. 8158622 - Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase (2012-04-17),

7. 8063247 - Bicyclic aryl and heteroaryl receptor modulators (2011-11-22),

8. 7745491 - Substituted phenylacetamides and their use as glucokinase activators (2010-06-29),

9. 7582632 - Tri(cyclo) substituted amide compounds (2009-09-01),

10. 7262196 - Tri(cyclo) substituted amide glucokinase activator compounds (2007-08-28),

11. 7214681 - Tri(cyclo) substituted amide compounds (2007-05-08),

12. 7166579 - Prodrugs of DP IV-inhibitors (2007-01-23),

13. 7083933 - Methods for identification of modulators of OSGPR116 activity (2006-08-01),

14. 7060719 - Glutaminyl based DPIV inhibitors (2006-06-13),

15. 7053055 - Compounds of unstable DP IV-inhibitors (2006-05-30),

Prosidion Limited is a biopharmaceutical company specializing in the development of novel therapies for metabolic diseases. With a focus on diabetes and obesity, Prosidion aims to bring innovative treatments to patients around the world. Through cutting-edge research and collaboration with leading scientists, Prosidion is committed to making a difference in the lives of those affected by these conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

16 Patents

#15 in Oxford

#1,107 in United Kingdom

#36,684 in the World

Oxford, United Kingdom

Prosidion Limited

Forward Citations = 101

39 inventors:

Martin James Procter (7 out of 24 patents)

Matthew Colin Thor Fyfe (7 out of 15 patents)

Karen Lesley Schofield (6 out of 12 patents)

4. Chrystelle Marie Rasamison (5 out of 6 patents)

5. Stuart Edward Bradley (5 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…